Rentschler Biopharma began its role as a contract development and manufacturing organization (CDMO) for biopharmaceuticals in 1997. Founded in 1872 as a pharmacy in Laupheim, Germany, the company ...

Multichain protein biotherapeutics such as bispecific molecules have been developed to treat cancer, neurological and ophthalmic disorders, and autoimmune and inflammatory diseases. Early successes ...

Biopharmaceutical giant GSK announced a site expansion at its Marietta, Pennsylvania site, where it will build a multipurpose manufacturing facility to produce sterile liquid vaccines and other ...

In 2021, Fujifilm began constructing a biomanufacturing site in Holly Springs, North Carolina at a cost of ¥200 billion (then $2 billion, now $1.3 billion) for its contract development manufacturing ...

The buildout of its $1.5 billion facility will establish the Anglo-Swedish drugmaker’s first manufacturing presence in Singapore. Additionally, it will be AstraZeneca’s first ADC plant to produce the ...

First reported by Reuters, this facility will potentially be used as a fill/finish plant to manufacture injection pens for Novo’s star weight loss drugs Wegovy and Ozempic (semaglutide). Confirming ...

Properly scaling from small-scale bioreactors to larger-scale bioreactors for intensified processes is highly dependent on maintaining mixing, oxygenation, nutrient, and process control. To be able to ...

Pluri signed a deal worth $4.2 million with the US National Institute of Allergy and Infectious Diseases (NIAID), a division of NIH, in 2023. $1.4 million of the total amount has been dedicated by NIH ...

Glucagon-like peptide-1 (GLP-1) drugs for diabetes and weight loss are emerging as the latest blockbuster pharmaceuticals. Like messenger RNA (mRNA) gaining recognition during the pandemic, the ...

The firms will co-commercialize the products globally, except for MK-6070 in Japan where Merck (known as MSD outside of the US and Canada) will retain the exclusive rights. Merck will also be solely ...

Contract development manufacturing organization (CDMO) MilliporeSigma – the life sciences division of Merck KGaA – will manufacture GMP-compliant dry powder and liquid CCM to support a wide range of ...

Sanofi will build a €1 billion ($1.1 billion) mAb production facility in Vitry-sur-Seine, while it invests €100 million to bolster capacity at its Le Trait site in Normandy and invests €10 million at ...